Gilead Sciences (GILD) Target Lifted to $96 at Citi
Tweet Send to a Friend
Citi reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target from $87 to $96.
This article: 177 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 177 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
